KalVista, Ionis/Sobi win EU nod for drugs (KALV:NASDAQ)

Group 1 - The European Commission has granted final approval for two treatments developed by KalVista Pharmaceuticals and Ionis Pharmaceuticals targeting rare genetic disorders [2][3]